Okami Medical

The UNC pulmonary arteriovenous malformations (PAVM) experience is now published. This single-center data set shows how the uniquely engineered LOBO device delivers promising results in this critical patient population. READ lnkd.in/gpc6nXpG LOBO lnkd.in/g7ZM9j6Y

"One of my favorite properties of LOBO is that there's essentially no streak artifact….Having something that doesn't impact the surrounding tissue in terms of visibility has been excellent." Just one way the LOBO system is reshaping embolization. Listen to Backtable for more.

We’re proud to announce the first patient enrolled in the ALPHA Registry, advancing real-world evaluation of the LOBO® Vascular Occluder. A key step in strengthening evidence for innovative embolization solutions. Read more: prnewswire.com/news-releases/…

The LOBO® Vascular Occluder is the first and only peripheral embolization device designed to provide complete occlusion with the deliverability and stability physicians need to navigate with confidence, even during the most complex embolization procedures. Discover LOBO at SIR.

Heading to SIR next week? Don't miss the LOBO lunch symposium! Join us for a case-based discussion on the LOBO device and discover how it's impacting embolization practice nationwide - through three unique perspectives. April 11, 12:10-1:10 pm, Room 801B okamimedical.com/events/sir/

LOBO®with HDBRAID® was designed to eliminate the need for multiple devices per vessel, resulting in higher efficiency and lower costs. Learn More: okamimedical.com/okami-economic…

We’re heading to SIR in Toronto and bringing the future of vascular occlusion with us. Learn about the LOBO® HDBRAID® Vascular Occluder. Attend: LOBO & GO: CASE-BASED LEARNINGS ON NEXT-GEN EMBOLIZATION, April 11, 12:10 – 1:10 pm, Room 801B. Register here: okamimedical.com/events/sir/

Built on decades of experience, our engineers created a new class of nitinol braiding—HDBRAID. Ultra-thin wires woven at high density form a breakthrough micro pore mesh for optimal occlusion, stability, and flexible delivery. LEARN MORE. okamimedical.com/lobo-technolog…

Register for our lunch symposium at SIR 2026. Join us for case-based learning with a panel of 3 experienced implanters highlighting the HDBRAID® difference in a wide range of cases. Saturday, April 11 from 12:10-1:10 pm, Room 801B Register: okamimedical.com/events/sir/ #SIR26TOR

A single LOBO9 device was deployed via a 6 Fr Ansel sheath to achieve occlusion of a collateral vessel measuring 7.7 mm in diameter. Successful embolization confirmed with angiography, with 5-minute occlusion time. Case from Dr. Gurvan Blackman. More Cases okamimedical.com/case-studies/

Okami Medical announces $45 million financing and new CEO appointment to drive next phase of growth. LEARN MORE prnewswire.com/news-releases/… #OkamiMedical #HDBRAID #LoboOccluder

We’re excited to announce that Drew Hykes has been appointed President & CEO of Okami Medical, effective Oct 6. Drew brings 20+ years of medtech leadership, most recently serving as CEO of Inari Medical. Welcome to the team, Drew! #Leadership #OkamiMedical

LOBO enables rapid, single-device vessel occlusion that may reduce procedure duration, fluoroscopy time, and total implant costs. Does this resonate? Get the full analysis and decide for yourself. okamimedical.com/okami-economic…

Why? Its unique design and deliverability make it a compelling alternative to traditional coil-based approaches. And it could save your practice hundreds (or thousands) per case. LOBO is changing how physicians think about embolization. Learn more okamimedical.com/okami-economic…

LOBO’s single-device design may help: – Eliminate ancillary embolics – Simplify inventory – Minimize implant-related costs It’s not just simpler. It’s smarter. See the full breakdown of the analysis for your practice. okamimedical.com/okami-economic…

Real-world data shows LOBO was chosen over coils in 80% of cases. Able to achieve occlusion with a single device and potential savings up to $204K per 100 cases. Why use more devices when 1 does it all? Get the full cost analysis to see how LOBO compares. okamimedical.com/okami-economic…

Okami Medical announces the appointment of Bill Hoffman to its Board of Directors. Mr. Hoffman brings extensive experience in the medical device industry and will be an invaluable asset as Okami expands the commercial reach of the LOBO® Vascular Occluder. hubs.la/Q02-fdsR0

The LOBO® HDBRAID® Vascular Occluder stops the bleeding clinically, procedurally and economically. One device in a wide range of cases with a 90 second average time to occlusion.* One. Done. LOBO. Learn more. hubs.la/Q02Z73Gp0 #Okamimedical #Lobooccluder

Coils and plugs come with limitations. Those limitations cost time and money. LOBO® stops the bleeding with a single device in a wide range of cases with a 90 second average time to occlusion.* Learn more. hubs.la/Q02XPGh_0 #Okamimedical #Lobooccluder

Join fellow VIVA attendees to learn how to stop the bleeding in 90 seconds* with a demo of the LOBO® HDBRAID® Vascular Occluder. VIVA booth 208. #Okamimedical #Lobooccluder #VIVA24